Positrigo appoints Qualimedis as Distributor in France
May 26, 2025
- Qualimedis to sell and offer technical service for the NeuroLF system in France.
- Complementary Positrigo and Qualimedis product portfolios to strengthen market position of both organizations.
Positrigo, a Swiss based company developing nuclear medical imaging devices to advance functional brain imaging, announced today the appointment of Qualimedis as its distribution partner in France. The distribution agreement covers the sale of the NeuroLF system and all after sales activities including technical service in France and started on May 1, 2025.
As a distributor with a strong presence in the medical imaging field in general and nuclear medicine in particular, Qualimedis is the ideal partner for Positrigo in France. The company has a nationwide sales and service team that has extensive experience in the commercialization of novel imaging technologies, training, education and after sales support. Qualimedis was selected from a broad field of potential distributors following a rigorous screening process.
“We are pleased to have found in Qualimedis a partner sharing the core Positrigo values of innovation, quality and commitment,” says Stefan Bircher, Chief Commercial Officer at Positrigo. “The product portfolio which Qualimedis represents is very complementary to our dedicated brain PET system. We are confident that this partnership will significantly boost our presence in France.”
The appointment of Qualimedis comes timely as just a few weeks ago the European Commission has authorized lecanemab (1) – a treatment for early Alzheimer’s disease – which is supposed to increase significantly the demand for brain PET scans according to the Neuroimaging Committee of the European Association of Nuclear Medicine (2).
Hervé Servajean, CEO of Qualimedis: “We are delighted to be selected as the partner for Positrigo in France. This partnership is completely in alignment with our strategy to further expand and strengthen our presence in the medical imaging sector. With our dedicated experts in nuclear medicine and our board product offering, we are fully committed to accelerate growth.”
About Positrigo:
Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Zurich, Switzerland, the medical device company was founded in 2018 as a spin-off of ETH Zurich. Positrigo’s technology, development, clinical testing and commercialization has been supported by various private investors, the Swiss government and the European Innovation Council. NeuroLF – the company’s first device – is an ultra-compact brain Positron Emission Tomography (PET) scanner which has applications in the assessment of causes of dementias, such as Alzheimer’s disease and other brain related disorders. NeuroLF is the first device of its kind with market authorization in the US and EU.
About Qualimedis:
Qualimedis was founded in 2008 and has specialized in providing innovative quality assurance solutions and devices in the medical use of ionizing radiation and in the medical imaging field. As the distributor of the different best Imaging companies, the company is committed to offer best in class imaging technologies supported by a best in class after sales support team.
References:
1 Commission authorises medicine for treatment of early Alzheimer’s disease